|
|
Blood, Vol. 110, Issue 13, 4427-4435, December 15, 2007
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells
Blood Guzman et al.
110: 4427
Supplemental materials for: Jordan et al
Files in this Data Supplement:
- Table S1. AML specimens (PDF, 406KB)
- Table S2. Other leukemia specimens (PDF, 318KB)
- Table S3. Normal specimens (PDF, 147KB)
- Figure S1. DMAPT does not significantly affect the viability of normal hematopoietic stem/progenitor cells (PDF, 23KB) -
Percent viability of normal CD34+ (left) or CD34+CD38− (right) hematopoietic cells shown in figure 1E obtained from healthy donors separated into CB or BM specimens. Cells were treated at the indicated concentrations of DMAPT. In all panels the horizontal bars represent the mean and each circle represents one specimen. Analysis of each specimen was performed in triplicate and the average was used to represent the results for a single specimen. All viability values are relative to untreated controls. Paired t-test for CB vs. BM showed that differences are not significant: for CD34+ at 5µM p= 0.2602; 7.5µM p= 0.3797 and for CD34+CD38− at 5µM p= 0.6207; 7.5µM p= 0.3906. The samples displaying lower viability correspond to N4 and N5 specimens (Table S3).
- Figure S2. NF-κB activity for primary canine leukemias and their response to DMAPT in vitro (PDF, 151KB) -
Each lane represents a different canine specimen. (A) NF- B EMSA on nuclear extracts obtained from spontaneous canine leukemias. (B) Percent viability of primary canine leukemia specimens treated at the indicated concentrations of DMAPT for 24 hours. Analysis of each specimen was performed in triplicate and the average was used to represent the results for a single specimen. (C) NF-B EMSA on nuclear extracts obtained from spontaneous canine leukemias after 6 hours of treatment with DMAPT (UT = untreated, DM = DMAPT treated).
- Figure S3. Primary canine leukemia cells are able to engraft NOD/SCID mice (PDF, 69KB) -
(A) Dot-plot of BM samples from NOD/SCID mice at 6 weeks after injection with canine leukemia specimens. Cells were stained with murine and canine specific CD45 antibodies to distinguish donor from host. The left panel shows a representative control plot negative for engraftment and the right panel shows positive canine engraftment. (B) Percentage of canine engraftment in NOD/SCID mice for pre-treatment specimens obtained for the three dogs subsequently treated with DMAPT (Figures 4-5). The horizontal line shows mean engraftment for each cohort. Each circle represents an individual recipient mouse.
- Figure S4. U937 differentiation assay for DMAPT treatment (PDF, 23KB) -
Percent CD11b expression after 72 hours treatment with sublethal concentrations of DMAPT. ATRA treatment is shown as control. Horizontal line represents CD11b levels in untreated control cells. ** p<0.001.
|
|
